미국의 세포배양 시장 규모, 점유율, 동향 분석 리포트 : 제품별, 용도별, 부문 예측(2024-2030년)

U.S. Cell Culture Market Growth & Trends:

The U.S. cell culture market size is anticipated to reach USD 10.97 billion by 2030 and is projected to grow at a CAGR of 10.02% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market growth is expected to be driven by various factors, such as the growth of biosimilars and biologics, advancements in stem cell research, and the emergence of bio-manufacturing technologies that facilitate the development of cell-based vaccines.

The COVID-19 pandemic has resulted in an increased demand for reliable cell-based vaccine production technologies. Furthermore, it has led to a few notable scientific breakthroughs, particularly in the development and testing of vaccine technologies. In August 2021, Danaher announced the manufacturing expansion of Cytiva and Pall which assisted in the drug and vaccine development for COVID and enabled expansion in manufacturing of various modalities such as cell culture and gene therapy to meet the demands during the pandemic.

Cell culture technology has witnessed significant advancements over the past few years and the technology is witnessing a rapid expansion in its scope of applications. In the field of biopharmaceuticals, researchers can now produce complex protein-based drugs in large quantities due to the ability to culture mammalian cells. This has led to increased efficiency, reduced costs, and improved quality control in the biopharmaceutical industry. Furthermore, the launch of high-yield cell lines and the optimization of culture conditions have contributed to enhanced productivity and scalability. For instance, in June 2023, Matica Bio launched its MatiMax cell lines at the BIO International Convention. The cell line features faster doubling times to reduce processing timelines, has enhanced transfection efficiencies, and enables increased titer production at a lower cost.

However, the growing awareness and debate surrounding the ethical implications of animals and animal-based products used in the life sciences industry is impeding market growth to a certain extent. Concerns ranging from conditions in which animals are housed and potential pain caused during procedures to the overall impact on the animal population are growing. However, the introduction of serum-free, protein-free media products is expected to overcome these limitations.

U.S. Cell Culture Market Report Highlights:

• The consumables segment led the market with the largest revenue share of 58.0% in 2023 and are expected to grow at the fastest CAGR during the forecast period. This is attributed to the increased R&D expenditure by biotechnology & biopharmaceutical businesses to develop sophisticated biologics, such as monoclonal antibodies & vaccines
• Based on application, the biopharmaceutical production segment led the market with the largest revenue share of 31.9% in 2023 and is expected to grow at the fastest CAGR during the forecast period. The technological advancements in antibody therapeutics, such as the development of bispecific antibodies, antibody fragments, and antibody derivatives, are anticipated to expand the market prospects for applications of cell culture

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Product Segment
  • 1.1.2. Application Segment
• 1.2. Estimates and Forecast Timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Primary Research
• 1.5. Information or Data Analysis:
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
• 1.8. List of Secondary Sources
• 1.9. List of Abbreviations
• 1.10. Objective

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables &Trends

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Expansion in the scope of applications for cell culture technology
    • 3.2.1.2. Rising demand for biopharmaceuticals, artificial organs, & vaccine production
    • 3.2.1.3. Growth in demand for serum-free, specialty, and customized media
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Stringent process control in cell culture techniques
    • 3.2.2.2. Scalability issues with culturing methods
    • 3.2.2.3. Ethical concerns regarding the use of animals
• 3.3. Industry Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Product Business Analysis

• 4.1. Product Segment Dashboard
• 4.2. U.S. Cell Culture Market Product Movement Analysis
• 4.3. U.S. Cell Culture Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
• 4.4. Consumables
  • 4.4.1. Consumables market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.4.2. Sera
    • 4.4.2.1. Sera market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.4.2.2. Fetal Bovine Serum
    • 4.4.2.2.1. Fetal bovine serum market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.4.2.3. Other
    • 4.4.2.3.1. Other market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.4.3. Reagents
    • 4.4.3.1. Reagents market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.4.3.2. Albumin
    • 4.4.3.2.1. Albumin market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.4.3.3. Other
    • 4.4.3.3.1. Other market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.4.4. Media
    • 4.4.4.1. Media market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.4.4.2. Serum-free Media
    • 4.4.4.2.1. Serum-free media market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.4.4.2.2. CHO Media
    • 4.4.4.2.2.1. CHO media market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.4.4.2.3. HEK 293 Media
    • 4.4.4.2.3.1. HEK 293 media market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.4.4.2.4. BHK Medium
    • 4.4.4.2.4.1. BHK medium market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.4.4.2.5. Vero Medium
    • 4.4.4.2.5.1. Vero medium market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.4.4.2.6. Other Serum-free Media
    • 4.4.4.2.6.1. Other serum-free media market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.4.4.3. Classical Media
    • 4.4.4.3.1. Classical media market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.4.4.4. Stem Cell Culture Media
    • 4.4.4.4.1. Stem cell culture media market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.4.4.5. Chemically Defined Media
    • 4.4.4.5.1. Chemically defined media market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.4.4.6. Specialty Media
    • 4.4.4.6.1. Specialty media market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.4.4.7. Other Cell Culture Media
    • 4.4.4.7.1. Other cell culture media market estimates and forecasts, 2018 - 2030 (USD Million)
• 4.5. Instruments
  • 4.5.1. Instruments market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.5.2. Culture Systems
    • 4.5.2.1. Culture systems market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.5.3. Incubators
    • 4.5.3.1. Incubators market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.5.4. Centrifuges
    • 4.5.4.1. Centrifuges market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.5.5. Cryostorage Equipment
    • 4.5.5.1. Cryostorage equipment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.5.6. Biosafety Equipment
    • 4.5.6.1. Biosafety equipment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.5.7. Pipetting
    • 4.5.7.1. Pipetting market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5. Application Business Analysis

• 5.1. Application Segment Dashboard
• 5.2. U.S. Cell Culture Market Application Movement Analysis
• 5.3. U.S. Cell Culture Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 5.4. Biopharmaceutical Production
  • 5.4.1. Biopharmaceutical production market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.4.2. Monoclonal Antibodies
    • 5.4.2.1. Monoclonal antibodies market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.4.3. Vaccine Production
    • 5.4.3.1. Vaccine production market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.4.4. Other Therapeutic Proteins
    • 5.4.4.1. Other therapeutic proteins market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.5. Drug Development
  • 5.5.1. Drug development market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.6. Diagnostics
  • 5.6.1. Diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.7. Tissue Culture and Engineering
  • 5.7.1. Tissue culture and engineering market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.8. Cell & Gene Therapy
  • 5.8.1. Cell & gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.9. Toxicity Testing
  • 5.9.1. Toxicity testing market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.10. Other Application
  • 5.10.1. Other applications market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Company Categorization
• 6.2. Strategy Mapping
• 6.3. Company Market Position Analysis, 2023
• 6.4. Company Profiles/Listing
  • 6.4.1. Sartorius AG
    • 6.4.1.1. Overview
    • 6.4.1.2. Financial Performance
    • 6.4.1.3. Product Benchmarking
    • 6.4.1.4. Strategic Initiatives
  • 6.4.2. Danaher
    • 6.4.2.1. Overview
    • 6.4.2.2. Financial Performance
    • 6.4.2.3. Product Benchmarking
    • 6.4.2.4. Strategic Initiatives
  • 6.4.3. Merck KGaA
    • 6.4.3.1. Overview
    • 6.4.3.2. Financial Performance
    • 6.4.3.3. Product Benchmarking
    • 6.4.3.4. Strategic Initiatives
  • 6.4.4. Thermo Fisher Scientific, Inc.
    • 6.4.4.1. Overview
    • 6.4.4.2. Financial Performance
    • 6.4.4.3. Product Benchmarking
    • 6.4.4.4. Strategic Initiatives
  • 6.4.5. Corning Inc.
    • 6.4.5.1. Overview
    • 6.4.5.2. Financial Performance
    • 6.4.5.3. Product Benchmarking
    • 6.4.5.4. Strategic Initiatives
  • 6.4.6. Avantor Inc.
    • 6.4.6.1. Overview Avantor Inc.
    • 6.4.6.2. Financial Performance
    • 6.4.6.3. Product Benchmarking
    • 6.4.6.4. Strategic Initiatives
  • 6.4.7. BD
    • 6.4.7.1. Overview
    • 6.4.7.2. Financial Performance
    • 6.4.7.3. Product Benchmarking
    • 6.4.7.4. Strategic Initiatives
  • 6.4.8. Eppendorf SE
    • 6.4.8.1. Overview
    • 6.4.8.2. Financial Performance
    • 6.4.8.3. Product Benchmarking
    • 6.4.8.4. Strategic Initiatives
  • 6.4.9. Bio-Techne
    • 6.4.9.1. Overview
    • 6.4.9.2. Financial Performance
    • 6.4.9.3. Product Benchmarking
    • 6.4.9.4. Strategic Initiatives
  • 6.4.10. PromoCell GmbH
    • 6.4.10.1. Overview
    • 6.4.10.2. Financial Performance
    • 6.4.10.3. Product Benchmarking
    • 6.4.10.4. Strategic Initiatives